Julio Echarte-Morales, Laura Sanchis, Dabit Arzamendi, Vanessa Moñivas, Fernando Carrasco-Chinchilla, Manuel Pan, Luis Nombela-Franco, Isaac Pascual, Tomás Benito-González, Ruth Pérez, Iván Gómez-Blázquez, Ignacio J Amat-Santos, Ignacio Cruz-González, Ángel Sánchez-Recalde, Ana Belén Cid Álvarez, Manuel Barreiro-Pérez, Pedro Cepas-Guillén, Chi Hion Li, María Del Trigo, José David Martínez-Carmona, Dolores Mesa, Patricia Mahía, Pablo Avanzas, André González-García, Xavier Freixa, Rodrigo Estévez-Loureiro
{"title":"边缘到边缘三尖瓣修复和心力衰竭住院:TRI-SPA登记。","authors":"Julio Echarte-Morales, Laura Sanchis, Dabit Arzamendi, Vanessa Moñivas, Fernando Carrasco-Chinchilla, Manuel Pan, Luis Nombela-Franco, Isaac Pascual, Tomás Benito-González, Ruth Pérez, Iván Gómez-Blázquez, Ignacio J Amat-Santos, Ignacio Cruz-González, Ángel Sánchez-Recalde, Ana Belén Cid Álvarez, Manuel Barreiro-Pérez, Pedro Cepas-Guillén, Chi Hion Li, María Del Trigo, José David Martínez-Carmona, Dolores Mesa, Patricia Mahía, Pablo Avanzas, André González-García, Xavier Freixa, Rodrigo Estévez-Loureiro","doi":"10.1016/j.rec.2025.02.015","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction and objectives The prognostic impact of a history of heart failure hospitalizations (HFH) in patients undergoing transcatheter tricuspid edge-to-edge repair (T-TEER) has been scarcely studied. This study presents the results of the TRI-SPA registry, which includes data from 15 Spanish centers. Methods A multicenter, retrospective registry was conducted, including patients who underwent T-TEER between June 2020 and May 2023. Patients were classified into the 3 groups, based on the number of HFH in the 12 months prior to the procedure: no HFH, 1 HFH, and > 1 HFH (recurrent). The primary endpoint was all-cause mortality and HFH. Results Of the 262 patients included, 167 (63.7%) had no history of HFH, 60 (22.9%) had 1 HFH, and 35 (13.4%) had > 1 HFH. Patients with > 1 hospitalization had more comorbidities, higher surgical risk, and worse functional class; however, no significant differences were observed in the severity of tricuspid regurgitation either at baseline or after T-TEER. After a median follow-up of 365 [160-643] days, patients with recurrent HFH had higher rates of the composite outcome (9.9%, 16.7%, and 43.1%, respectively; P < .001), as well as higher mortality rates (P = .036) and HFH (P < .001). The number of HFH significantly decreased in the 12 months following T-TEER compared with the 12 months prior (P = .001). Conclusions Recurrent HFH within the 12 months prior to the procedure was associated with a higher risk of adverse clinical events during follow-up. T-TEER significantly reduced the number of hospitalizations during the follow-up period. Full English text available from: www.revespcardiol.org/en.</p>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":" ","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Edge-to-edge tricuspid valve repair and heart failure hospitalizations: the TRI-SPA registry.\",\"authors\":\"Julio Echarte-Morales, Laura Sanchis, Dabit Arzamendi, Vanessa Moñivas, Fernando Carrasco-Chinchilla, Manuel Pan, Luis Nombela-Franco, Isaac Pascual, Tomás Benito-González, Ruth Pérez, Iván Gómez-Blázquez, Ignacio J Amat-Santos, Ignacio Cruz-González, Ángel Sánchez-Recalde, Ana Belén Cid Álvarez, Manuel Barreiro-Pérez, Pedro Cepas-Guillén, Chi Hion Li, María Del Trigo, José David Martínez-Carmona, Dolores Mesa, Patricia Mahía, Pablo Avanzas, André González-García, Xavier Freixa, Rodrigo Estévez-Loureiro\",\"doi\":\"10.1016/j.rec.2025.02.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Introduction and objectives The prognostic impact of a history of heart failure hospitalizations (HFH) in patients undergoing transcatheter tricuspid edge-to-edge repair (T-TEER) has been scarcely studied. This study presents the results of the TRI-SPA registry, which includes data from 15 Spanish centers. Methods A multicenter, retrospective registry was conducted, including patients who underwent T-TEER between June 2020 and May 2023. Patients were classified into the 3 groups, based on the number of HFH in the 12 months prior to the procedure: no HFH, 1 HFH, and > 1 HFH (recurrent). The primary endpoint was all-cause mortality and HFH. Results Of the 262 patients included, 167 (63.7%) had no history of HFH, 60 (22.9%) had 1 HFH, and 35 (13.4%) had > 1 HFH. Patients with > 1 hospitalization had more comorbidities, higher surgical risk, and worse functional class; however, no significant differences were observed in the severity of tricuspid regurgitation either at baseline or after T-TEER. After a median follow-up of 365 [160-643] days, patients with recurrent HFH had higher rates of the composite outcome (9.9%, 16.7%, and 43.1%, respectively; P < .001), as well as higher mortality rates (P = .036) and HFH (P < .001). The number of HFH significantly decreased in the 12 months following T-TEER compared with the 12 months prior (P = .001). Conclusions Recurrent HFH within the 12 months prior to the procedure was associated with a higher risk of adverse clinical events during follow-up. T-TEER significantly reduced the number of hospitalizations during the follow-up period. Full English text available from: www.revespcardiol.org/en.</p>\",\"PeriodicalId\":38430,\"journal\":{\"name\":\"Revista española de cardiología (English ed.)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista española de cardiología (English ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.rec.2025.02.015\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista española de cardiología (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.rec.2025.02.015","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Edge-to-edge tricuspid valve repair and heart failure hospitalizations: the TRI-SPA registry.
Introduction and objectives The prognostic impact of a history of heart failure hospitalizations (HFH) in patients undergoing transcatheter tricuspid edge-to-edge repair (T-TEER) has been scarcely studied. This study presents the results of the TRI-SPA registry, which includes data from 15 Spanish centers. Methods A multicenter, retrospective registry was conducted, including patients who underwent T-TEER between June 2020 and May 2023. Patients were classified into the 3 groups, based on the number of HFH in the 12 months prior to the procedure: no HFH, 1 HFH, and > 1 HFH (recurrent). The primary endpoint was all-cause mortality and HFH. Results Of the 262 patients included, 167 (63.7%) had no history of HFH, 60 (22.9%) had 1 HFH, and 35 (13.4%) had > 1 HFH. Patients with > 1 hospitalization had more comorbidities, higher surgical risk, and worse functional class; however, no significant differences were observed in the severity of tricuspid regurgitation either at baseline or after T-TEER. After a median follow-up of 365 [160-643] days, patients with recurrent HFH had higher rates of the composite outcome (9.9%, 16.7%, and 43.1%, respectively; P < .001), as well as higher mortality rates (P = .036) and HFH (P < .001). The number of HFH significantly decreased in the 12 months following T-TEER compared with the 12 months prior (P = .001). Conclusions Recurrent HFH within the 12 months prior to the procedure was associated with a higher risk of adverse clinical events during follow-up. T-TEER significantly reduced the number of hospitalizations during the follow-up period. Full English text available from: www.revespcardiol.org/en.